Incretin hormones, principally glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1), potentiate meal-stimulated insulin secretion through direct …

abstract Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and
glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along …

Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide and
GLP-1 receptor agonist under development for the treatment of type 2 diabetes. We aimed to …

The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Gut hormones orchestrate pivotal physiological processes in multiple metabolically active
tissues, including the pancreas, liver, adipose tissue, gut and central nervous system …

Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist. In this phase 3, randomized, open-
label trial, insulin-naive adults (≥ 18 years of age) with type 2 diabetes (T2D) uncontrolled …

The history of anti-obesity pharmacotherapies is marked by disappointments, often
entangled with societal pressure promoting weight loss and the prevailing conviction that …

Obesity and type 2 diabetes mellitus (T2DM) are widespread, non-communicable diseases
that are responsible for considerable levels of morbidity and mortality globally, primarily in …

Tirzepatide is a novel glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide
1 (GLP‐1) receptor agonist approved in the United States as an adjunct to diet and exercise …

Glucagon-like peptide 1 receptor (GLP-1R) and glucose-dependent insulinotropic
polypeptide receptor (GIPR) are two class B1 G protein-coupled receptors, which are …